One Global Service Provider Limited

One Global Service Provider Limited (ONEGLOBAL) operates in the healthcare services and IT & Software Solutions sectors. The company provides medical and diagnostic equipment, hospital furniture, laboratory analysers, reagents, consumables, chemicals, and allied software services such as LIS, MIS, and HIMS. It also manages laboratories offering diagnostic services, preventive healthcare, and population screening, with a global reach for healthcare solutions and a presence in India.

Key facts (based on FY 2025-26 Annual Report):

• Total Revenue for FY 2025-26 was Rs. 49,881.06 lakhs.
• Profit After Tax (PAT) for FY 2025-26 was Rs. 6,950.42 lakhs.
• Return on Equity (RoE) stood at 49.21% for FY 2025-26.
• The company reported a Debt-Equity Ratio of 0.00 for FY 2025-26, indicating no outstanding debt.
• Mr. Sanjay Lalbhadur Upadhaya serves as the Chairman & Managing Director and is a promoter.
• As of March 31, 2026, 95.61% of the company's paid-up equity share capital was held in dematerialized form.

Recent developments (from AR FY 2025-26):

• The company experienced significant growth in FY 2025-26, driven by the amalgamation of Plus Care Internationals Private Limited.
• The Board approved the proposed acquisition of a 51% stake in Matrix Labs Diagnocare Private Limited (MLDPL) and Matrix Labs Private Limited (MLPL) for a non-cash consideration via preferential issuance of 7,15,040 equity shares.
• The Authorized Share Capital is proposed to be increased from Rs. 25.05 Crore to Rs. 50.00 Crore to facilitate future capital requirements.
• Borrowing limits are proposed to be enhanced up to Rs. 1000 Crore to support expanding business activities and strategic objectives.
• The company plans to enter into related party transactions with Lifenity Health Limited (LHL) for FY 2026-27, estimated at Rs. 500 Crore, involving goods, services, and asset transactions.

Key risks flagged by management (from AR FY 2025-26):

• The healthcare industry faces increased consolidation and government intervention, including price control and margin capping, impacting profitability.
• Inflationary pressures, slowdown in policy making, competition from local and multinational players, and execution risk are noted as major setbacks.
• Regulatory changes and the challenge of attracting and retaining human capital pose ongoing threats to the business.
• Liquidity risk is monitored through continuous analysis of projected cash inflow and outflow and maintaining a balance between funding sources.

Pros:

• Achieved substantial financial growth in FY 2025-26, with total revenue increasing by 237.5% and PAT by 276.4% year-over-year.
• Maintained a zero Debt-Equity Ratio, indicating a strong capital structure and financial independence.
• Strategic acquisitions in the diagnostics sector and a dual focus on healthcare and IT solutions position the company for leveraging digital health and enterprise software opportunities.

Cons:

• The significant financial growth reported for FY 2025-26 was primarily driven by amalgamation, making it difficult to assess organic growth.
• A material related party transaction of Rs. 500 Crore is proposed with Lifenity Health Limited (LHL) for FY 2026-27, where ONEGLOBAL’s Managing Director also serves as a Director, indicating potential related party exposure.
• The Secretarial Audit Report for FY 2025-26 noted a delay in the submission of the Integrated Filing (Governance) for March 31, 2025, indicating a compliance lapse.